|
|
|
European Biopharmaceutical Review
|
The current advances in immunoncology are constantly rewriting the landscape of this field and changing the standard care of many types of cancer. Immunotherapy harnesses the immune system to fight cancer, and recent research has focused on teasing tumour cells out from their protective microenvironments by exposing them to the patient’s immune response, which has led to the development of new immunotherapies.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Dr Katie Chapple is a Scientist at Sartorius Stedim Biotech, working within the technical development team. She joined the company in 2016, following the successful completion of a PhD in neuroimmunology at University of Glasgow, UK, which focused on the autoantibody response in multiple sclerosis. Katie’s current position builds on her already-rounded knowledge of assay development, with an emphasis on using complex immunoassays to better understand treatment responses. Her role focuses on flow cytometry assay development and using this platform as a powerful tool to characterise mAb’s MOA.
Andrea Gomez-Donart is an Associate Scientist in the cell analytics branch of Sartorius Stedim Biotech, working within the R&D assay development team. She joined Sartorius in 2018 after 18 years of research in the applied toxicology field, testing preclinical drugs for efficacy, toxicity, and biodistribution. Andrea is currently an active member of the assay development group, designing assay kits to be used on the IntelliCyt iQue® Screener Plus highthroughput flow cytometry platform.
|
|
|
Dr Katie Chapple |
|
|
|
|
Andrea Gomez-Donart |
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins
WALTHAM, Mass., Jan. 5, 2022 /PRNewswire/ -- Thermo Fisher Scientific
Inc. (NYSE:TMO), the world leader in serving science, and PeproTech,
Inc., a leading developer and manufacturer of recombinant proteins,
today announced that Thermo Fisher completed its acquisition of
PeproTech on December 30, 2021 for a total cash purchase price of
approximately $1.85 billion.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial Labelling – More Than Just Labels
Faubel & Co. Nachfolger GmbH
Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >> |
|
|
.jpg)
